Dennis Ding
Stock Analyst at Jefferies
(0.83)
# 3,918
Out of 4,981 analysts
14
Total ratings
22.22%
Success rate
-8.23%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dennis Ding
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MLYS Mineralys Therapeutics | Maintains: Hold | $15 → $26 | $37.10 | -29.92% | 2 | Sep 3, 2025 | |
| INDV Indivior | Assumes: Buy | $20 | $23.21 | -13.83% | 1 | Jul 22, 2025 | |
| CRNX Crinetics Pharmaceuticals | Upgrades: Buy | $55 | $34.00 | +61.76% | 1 | Jan 22, 2025 | |
| IKT Inhibikase Therapeutics | Initiates: Buy | $8 | $1.56 | +412.82% | 1 | Nov 8, 2024 | |
| ASMB Assembly Biosciences | Upgrades: Buy | $2 → $35 | $21.80 | +60.59% | 1 | Sep 20, 2024 | |
| FOLD Amicus Therapeutics | Initiates: Buy | $18 | $7.99 | +125.28% | 1 | Sep 6, 2024 | |
| ABUS Arbutus Biopharma | Maintains: Buy | $5 → $7 | $4.46 | +56.95% | 2 | Sep 5, 2024 | |
| RXRX Recursion Pharmaceuticals | Maintains: Hold | $8 → $6 | $4.83 | +24.22% | 1 | Sep 3, 2024 | |
| LYRA Lyra Therapeutics | Downgrades: Hold | $500 → $25 | $6.29 | +297.46% | 1 | May 7, 2024 | |
| CORT Corcept Therapeutics | Downgrades: Hold | $35 → $22 | $72.87 | -69.81% | 1 | Feb 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $24.19 | -0.79% | 1 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $14.08 | -28.98% | 1 | Oct 26, 2021 |
Mineralys Therapeutics
Sep 3, 2025
Maintains: Hold
Price Target: $15 → $26
Current: $37.10
Upside: -29.92%
Indivior
Jul 22, 2025
Assumes: Buy
Price Target: $20
Current: $23.21
Upside: -13.83%
Crinetics Pharmaceuticals
Jan 22, 2025
Upgrades: Buy
Price Target: $55
Current: $34.00
Upside: +61.76%
Inhibikase Therapeutics
Nov 8, 2024
Initiates: Buy
Price Target: $8
Current: $1.56
Upside: +412.82%
Assembly Biosciences
Sep 20, 2024
Upgrades: Buy
Price Target: $2 → $35
Current: $21.80
Upside: +60.59%
Amicus Therapeutics
Sep 6, 2024
Initiates: Buy
Price Target: $18
Current: $7.99
Upside: +125.28%
Arbutus Biopharma
Sep 5, 2024
Maintains: Buy
Price Target: $5 → $7
Current: $4.46
Upside: +56.95%
Recursion Pharmaceuticals
Sep 3, 2024
Maintains: Hold
Price Target: $8 → $6
Current: $4.83
Upside: +24.22%
Lyra Therapeutics
May 7, 2024
Downgrades: Hold
Price Target: $500 → $25
Current: $6.29
Upside: +297.46%
Corcept Therapeutics
Feb 15, 2023
Downgrades: Hold
Price Target: $35 → $22
Current: $72.87
Upside: -69.81%
Dec 19, 2022
Initiates: Buy
Price Target: $24
Current: $24.19
Upside: -0.79%
Oct 26, 2021
Initiates: Buy
Price Target: $10
Current: $14.08
Upside: -28.98%